Mektovi (Binimetinib)

Binimetinib selectively blocks MEK1 and MEK2 kinases, preventing activation of the downstream ERK proteins. This interruption of the MAPK/ERK cascade reduces signals that drive cancer cell growth and survival, thereby limiting tumor progression.

The dosage of Mektovi is individualized by the treating physician based on clinical guidelines, patient characteristics, and tolerability. Healthcare providers determine the appropriate strength, frequency, and duration of therapy for each patient.

Safety data for binimetinib in pregnancy and lactation are limited, and the potential risk to the fetus or infant is unknown. Consequently, Mektovi is generally avoided in pregnant or nursing women unless the potential benefit justifies the risk.

To request Mektovi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mektovi (binimetinib) is one of several MEK inhibitors approved for melanoma. Compared with alternatives such as trametinib, binimetinib has a distinct safety profile and may be selected based on specific patient factors, prior therapies, and physician preference. Clinical efficacy is generally comparable when used in the appropriate indication.

Mektovi tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiration date.

Mektovi is taken orally as a tablet, usually with or without food, according to the prescribing physician’s instructions. Patients should swallow the tablet whole with water and follow the dosing schedule provided by their healthcare professional.

Serious adverse events include interstitial lung disease, retinal disorders that may affect vision, significant liver enzyme elevations, cardiac dysfunction such as reduced ejection fraction, severe skin reactions like Stevens‑Johnson syndrome, and increased bleeding risk. Patients should report any new symptoms promptly.

Mektovi is contraindicated in patients with known hypersensitivity to binimetinib or any tablet excipients. It should also be avoided in individuals with uncontrolled cardiac disease, severe hepatic impairment, or active retinal conditions, unless a specialist determines that the benefits outweigh the risks.